Mylan Inc. is set to ship acarbose tablets in 25-mg, 50-mg and 100-mg dosages, indicated to aid in the management of diabetes.


Mylan, acarbose tablets, Precose, Precose generic, Mylan Pharmaceuticals, Bayer, diabetes, type 2 diabetes, glycemic control, Food and Drug Administration, Precose tablets










































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan gets OK for Precose generic

January 18th, 2011

PITTSBURGH – Mylan Inc. is set to ship acarbose tablets in 25-mg, 50-mg and 100-mg dosages, indicated to aid in the management of diabetes.

The company said Tuesday that its Mylan Pharmaceuticals Inc. subsidiary has received final approval from the Food and Drug Administration for its abbreviated new drug application (ANDA) for acarbose tablets, the generic version of Bayer's Precose tablets.

Acarbose tablets are intended to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

Mylan reported that acarbose tablets had U.S. sales of about $23 million for the 12 months ended Sept. 30, 2010, based on data from IMS Health.

Advertisement